RNA · Atrium Therapeutics
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California. Atrium Therapeutics, Inc. was formerly a subsidiary of Avidity Biosciences, Inc.
Market Cap
149.3M
52 Wk Range
$6.36 - $16.77
Previous Close
$6.98
Open
$7.01
Volume
319,659
Day Range
$6.88 - $7.44
Enterprise Value
-82.12M
Cash
232.1M
Avg Qtr Burn
-25.37M
Insider Ownership
3.30%
Institutional Own.
66.71%
Qtr Updated
Sep 30th 2026
